Seminarios, Cursos y Redes Internacionales

Seminarios de Investigación

Los Seminarios de Investigación son una serie de Conferencias y Jornadas (en español y en inglés) que se organizan desde la Facultad de Farmacia y que permiten a los alumnos adquirir conocimientos en diferentes Áreas y complementar así el programa formativo de acuerdo con el interés profesional del alumno, además de consolidar su destreza en el idioma inglés

Responsable: Nuria del Olmo Izquierdo

Fecha Ponente Tema
25 de octubre de 2016 Nuria Montserrat

Dreaming with organ regeneration: new hopes for regenerative medicine

12 de diciembre de 2016 David Baeza

La investigación en una pyme

19 de diciembre de 2016 Carmen González Martín

Puesta a punto de una Unidad de Investigación Traslacional

30 de enero de 2017 Peter F. Hitchcock

Identifying drug targets that will inhibit CNS degeneration or stimulate CNS regeneration

6 de febrero de 2017 Lourdes Samaniego

La fortificación de los alimentos con ácido fólico como medida de salud pública: luces y sombras

13 de febrero de 2017 Nuria del Olmo

Efectos de la administración intermitente y excesiva de alcohol en los procesos de aprendizaje y memoria

20 de febrero de 2017 Lucciana Vaccaro

Primeros casos de Legionella no-pneumophila

23 de febrero de 2017 Josefa Zaldívar

Las aventuras de una estudiante del CEU en Harvard

27 de febrero de 2017 Maria Isabel Panadero

Fructosa y programación fetal del síndrome metabólico

6 de marzo de 2017 Javier Pérez Castell

Síntesis de azúcares coordinados con lantánidos y su uso para investigar los procesos de interacción entre proteínas y carbohidratos

13 de marzo de 2017 Mariano Ruiz-Gayo

Papel de la colecistoquinina en el metabolismo del tejido adiposo

27 de marzo de 2017 Coral Barbas

Por confirmar

3 de abril de 2017 Pedro Antonio Jiménez

Multiresistencia a Antibióticos y modulación Quorum sensing – Quorum Quenching

24 de abril de 2017 Sara Bueno

Control de la miopía con lentes de contacto

8 de mayo de 2017 Luis Fernando Alguacil

Adicción a los opiáceos

Cursos Y Redes

  • Conferencia Nacional de Decanos de Farmacia de España
    http://www.decanosfarmacia.org
  • Conferencia de Decanos y Directores de Nutrición Humana y Dietética
    http://www.cddnutricion.com
  • DIETS Thematic Network for Dietetics
    http://www.thematicnetworkdietetics.eu/everyone
  • Paul Ehrlich MedChem Euro-PhD
    http://www.pehrlichmedchem.eu
  • COST Action – BM1003 Microbial cell surface determinants of virulence as targets for new therapeutics in Cystic Fibrosis
    http://www.cost-bm1003.info

    The main aim of BM1003 action is to create an integrated network of excellence involving collaboration between experts in the multi-disciplinary fields of science required for understanding microbial cell surface determinants of virulence, antibiotic resistance and inflammation.

    Cystic fibrosis disease

    Cystic fibrosis (CF) causes constitutive inflammation in many organs and it particularly affects the lung. Chronic airway inflammation with chronic bacterial infections becomes established in most patients and it may lead to lung damage, destruction and eventually death. The bacterial factors and the molecular mechanisms which provoke inflammation in the respiratory epithelium of cystic fibrosis patients remain unclear. This topic is tackled using a coordinated and interdisciplinary approach by joining efforts by 16 European Countries, being Universidad CEU San Pablo member of the Management Committee. Competencies range from chemistry to microbiology and medicine. This multi- and inter-disciplinary approach is aimed at enabling the development of novel antibacterial inhibitors for anti-inflammatory therapy in cystic fibrosis patients.

    Reasons for the Action

    The major reasons for launching this Action are to rapidly develop novel therapies for CF and non-CF patient groups at risk for lung infections with opportunistic Gram-positive and Gram-negative bacterial pathogens. This aim will be achieved by the coordination of researchers into a European network of the already funded national research. Networking will also avoid repetition or duplication of scientific work and thus spare valuable resources of prior isolated research groups in Europe. We will create a defined panel of clinically relevant bacterial pathogens as an open user resource. This COST Action will enable researchers to develop novel inhibitors of bacterial cell wall synthesis with the aim to reduce lung inflammation in CF airways and to eradicate the pathogens with novel treatment strategies. This will increase the life expectancy of the CF patients. The pathogens that will be studied are also known to affect other patient groups including patients with immunodeficiencies such as burns patients and ventilated patients in critical care units. Also in these large patient groups, mortality due to respiratory infections is high. Improvement in knowledge of bacterial pathogenesis would have important implications for these patient groups, the quality of life of affected individual, and with the potential to reduce the inappropriate use of currently administered antibiotics, which increase the number of resistant pathogens in the European community.